Ironwood Pharma Statistics
Want to see IRWD full AI Analyst Report?
Ironwood Pharma (IRWD) Stock Statistics & Valuation Metrics
Total Valuation
Ironwood Pharma has a market cap or net worth of $796.30M. The enterprise value is $917.50M.
- Market Cap
- $796.30M
- Enterprise Value
- $917.50M
Share Statistics
Ironwood Pharma has 165,550,770 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 165,550,770
- Owned by Insiders
- 3.81%
- Owned by Institutions
- 38.23%
Financial Efficiency
Ironwood Pharma’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is 11.39%.
- Return on Equity (ROE)
- -0.09
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 11.39%
- Return on Capital Employed (ROCE)
- 0.77
- Revenue Per Employee
- 2.96M
- Profits Per Employee
- 240.17K
- Employee Count
- 100
- Asset Turnover
- 0.75
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Ironwood Pharma is 5.31. Ironwood Pharma’s PEG ratio is 0.01.
- PE Ratio
- 5.31
- PS Ratio
- 1.99
- PB Ratio
- -8.22
- Price to FCF
- 4.28
- Price to Operating Cash Flow
- 4.30
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Ironwood Pharma had revenue of 296.15M and earned 24.02M in profits. Earnings per share was 0.15.
- Revenue
- 296.15M
- Gross Profit
- 296.15M
- Operating Income
- 118.76M
- Pretax Income
- 70.03M
- Net Income
- 24.02M
- EBITDA
- 104.65M
- Earnings Per Share (EPS)
- 0.15
Cash Flow
In the last 12 months, operating cash flow was 185.56M and capital expenditures -1,000, giving a free cash flow of 185.55M billion.
- Operating Cash Flow
- 185.56M
- Free Cash Flow
- 185.55M
- Free Cash Flow per Share
- 1.12
Dividends & Yields
Ironwood Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 22.92%
- Earnings Yield
- 18.40%
Stock Price Statistics
- Beta
- 0.84
- 52-Week Price Change
- 90.12%
- 50-Day Moving Average
- 3.92
- 200-Day Moving Average
- 3.94
- Relative Strength Index (RSI)
- 75.98
- Average Volume (3m)
- 2.02M
Important Dates
Ironwood Pharma upcoming earnings date is Feb 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Ironwood Pharma as a current ratio of 1.13, with Debt / Equity ratio of -228.31%
- Current Ratio
- 1.13
- Quick Ratio
- 1.13
- Debt to Market Cap
- 1.07
- Net Debt to EBITDA
- 3.65
- Interest Coverage Ratio
- 3.63
Taxes
In the past 12 months, Ironwood Pharma has paid 46.01M in taxes.
- Income Tax
- 46.01M
- Effective Tax Rate
- 0.66
Enterprise Valuation
Ironwood Pharma EV to EBITDA ratio is 2.84, with an EV/FCF ratio of 3.96.
- EV to Sales
- 1.83
- EV to EBITDA
- 2.84
- EV to Free Cash Flow
- 3.96
- EV to Operating Cash Flow
- 3.96
Balance Sheet
Ironwood Pharma has $79.13M in cash and marketable securities with $396.87M in debt, giving a net cash position of -$317.74M billion.
- Cash & Marketable Securities
- $79.13M
- Total Debt
- $396.87M
- Net Cash
- -$317.74M
- Net Cash Per Share
- -$1.92
- Tangible Book Value Per Share
- -$0.99
Margins
Gross margin is 99.89%, with operating margin of 62.84%, and net profit margin of 37.38%.
- Gross Margin
- 99.89%
- Operating Margin
- 62.84%
- Pretax Margin
- 56.70%
- Net Profit Margin
- 37.38%
- EBITDA Margin
- 64.64%
- EBIT Margin
- 64.30%
Analyst Forecast
The average price target for Ironwood Pharma is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $6.00
- Price Target Upside
- 24.74% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 18.09%
- EPS Growth Forecast
- 403.76%
Scores
- Smart Score
- 10
- AI Score
- 72
